18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

• Status: Terminated
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erik Mittra
• Collaborator: National Cancer Institute (NCI)
• Treatments: Dihydroxyphenylalanine

Criteria

Inclusion Criteria:

• Greater than 15 year-old at the time of radiotracer administration

• Provides written informed consent

• Suspected new diagnosis or suspected recurrence of glioma

• Able to remain still for duration of each imaging procedure (about 20 minutes)

Exclusion Criteria:

• Less than 15 year-old at the time of radiotracer administra

• Unable to provide informed consent

• Inability to lie still for the entire imaging time

• Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

• Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance